Project Grant R01CA300296
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $636K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98101, USA
Similar Awards
- This National Cancer Institute (NCI) Project Grant award to Georgetown University, under the Cancer Biology Research program (CFDA 93.396), provides funding of $401,115 to develop a 3D bioengineered microfluidic platform (3D-BMP) to study the mechanisms of Ewing sarcoma bone metastasis. The project aims to utilize this 3D-BMP model to perform CRISPR screens and identify key genetic drivers of Ewing sarcoma's ability to metastasize to bone, a common occurrence that is associated with poor...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Nebraska Medical Center (UNMC) a Project Grant of $391,186 under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, with a completion date of August 31, 2027. This research project focuses on co-targeting insulin-like growth factor 1 receptor (IGF-1R) and glutaminase in Ewing sarcoma, a pediatric and young adult bone malignancy with poor survival outcomes once...
- Federal Project Grant Summary Seattle Children's Research Institute received a $434,361 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2027. The award funds the development of multispecific T cell engaging (MTE) therapy targeting mixed-phenotype acute leukemia (MPAL), a high-risk leukemia subtype with poor prognosis, particularly in adult patients over 40 years of age where overall...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Grant Award Summary The National Cancer Institute awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) a $3.48 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. This project systematically identifies genomic heterogeneity and relapse predictors in pediatric and adolescent/young adult patients with Philadelphia chromosome-positive (PH+) and ABL-class PH-like acute...
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a $640,135 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025 through July 31, 2030. This award supports the development of next-generation menin inhibitors designed to overcome clinical resistance observed in acute myeloid leukemia (AML) patients undergoing menin inhibitor therapy. The research addresses the critical clinical problem of...
- Federal Project Grant Award Summary Seattle Children's Hospital, doing business as Seattle Children's Research Institute, received a $470,759 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period September 1, 2025, through August 31, 2027. The award supports the development of PA-Regulator Controlled, JMJD6 Reprogrammed GPC3-CAR T Cells for patients with hepatocellular carcinoma. The research addresses a critical...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $217,600 Project Grant to New York University School of Medicine under the Cancer Research Manpower program (CFDA 93.398) on September 26, 2025, with a completion date of March 31, 2029. This award supports biomedical research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. The research project focuses on understanding T cell acute lymphoblastic...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Biology Research program (CFDA 93.396) for the period of May 1, 2026 through April 30, 2028. This award supports fundamental research investigating the innate and adaptive determinants of cytokine release syndrome (CRS) following chimeric antigen receptor (CAR) T-cell therapy. The research aims to elucidate the molecular mechanisms underlying...
- Federal Grant Award Summary Seattle Children's Hospital, doing business as Seattle Children's Research Institute, received a $456,414 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2025, through April 30, 2030. This award supports the clinical development and evaluation of B7-H3 Chimeric Antigen Receptor (CAR) T cell therapy for children and young adults with Diffuse Intrinsic Pontine Glioma (DIPG), a fatal...